CSIMarket Company Name, Ticker, Suppliers, else..
 
Adial Pharmaceuticals Inc   (NASDAQ: ADIL)
 
Price: $7.1200 $0.46 6.907%
Day's High: $7.199999809265137 Week Perf: 23.83 %
Day's Low: $ 6.27 30 Day Perf: 48.33 %
Volume (M): 48,386 52 Wk High: $ 10.75
Volume (M$): $ 0 52 Wk Avg: $4.76
Open: $6.61 52 Wk Low: $1.31



 Market Capitalization (Millions $) 33
 Shares Outstanding (Millions) 5
 Employees 6
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -58
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in Charlottesville, Virginia. The company focuses on the development of precision medicines for the treatment of alcohol use disorder (AUD) and other addictive disorders. Adial Pharmaceuticals' lead product is AD04, a therapeutic compound designed to reduce the desire to consume alcohol. The company aims to address the significant unmet need for effective pharmacotherapies for AUD, which currently lacks adequate treatment options. Adial Pharmaceuticals is committed to improving the lives of individuals suffering from alcohol addiction through innovative research and development efforts.


   Company Address: 4870 Sadler Road Glen Allen 23060 VA
   Company Phone Number: 487-8196   Stock Exchange / Ticker: NASDAQ ADIL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALKS   -2.76%    
NVCT        3.2% 
TVRD        4.95% 
VTGN   -2.88%    
ZYME        3.25% 
NBIX        1.03% 
• View Complete Report
   



Clinical Study

Adial Pharmaceuticals Advances Development of AD04 Positive Pharmacokinetics Results for Alcohol Use Disorder Treatment

Published Thu, Nov 14 2024 1:30 PM UTC

In a significant advancement in the treatment of alcohol use disorder (AUD), Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company, recently reported positive topline results from its AD04-103 pharmacokinetics study of AD04, a novel therapeutic agent designed to address addiction and related disorders. The study findings suggest that AD04 exh...
Management Announcement

Adial Pharmaceuticals on the Horizon of Change: Financial Challenges and Breakthroughs in Alcohol Use Disorder Treatment,

Published Wed, Nov 13 2024 1:30 PM UTC

Overview of Financial PerformanceAdial Pharmaceuticals, Inc. (NASDAQ: ADIL), a pioneering biopharmaceutical firm based in Glen Allen, Virginia, recently published its financial results for the third quarter of 2024 and provided a comprehensive business update. The company operates in the healthcare sector, focusing on the development of therapies aimed at treating and preve...
Management Announcement

“Adial Pharmaceuticals Pioneers New Pathways for Alcohol Use Disorder Treatment in Light of Evolving Recovery Definitions,

Published Tue, Oct 15 2024 1:01 PM UTC

Advancements in Alcohol Use Disorder Treatment: Adial Pharmaceuticals and the Evolving Landscape of Recovery DefinedIn a pivotal moment for the treatment of Alcohol Use Disorder (AUD), Adial Pharmaceuticals is at the forefront of innovation, aligning its research efforts with the National Institute on Alcohol Abuse and Alcoholism s (NIAAA) newly defined parameters for recove...
Clinical Study

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Diso...

Published Thu, Sep 19 2024 12:30 PM UTC

Adial Pharmaceuticals Advances Precision Medicine Approach for Alcohol Use Disorder with Promising Developments in AD04 Clinical Trials and ResearchAdial Pharmaceuticals is making significant strides in the field of precision medicine for the treatment of Alcohol Use Disorder (AUD) with its flagship investigational drug, AD04. The company recently announced several key mile...
Clinical Study

Adial Pharmaceuticals to Highlight Breakthroughs in Addiction Treatment at H.C. Wainwright Global Investment Co...

Published Wed, Sep 4 2024 1:01 PM UTC

GLEN ALLEN, Va. Sept. 04, 2024 Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment and prevention of addiction and related disorders, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled to take place from Sep...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.51
Working Capital Ratio 5.59
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -17.72 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 6.1 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -9,633,534
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.